(COG AALL1131) A Phase III Randomized Trial for Newly Diagnosed High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Description: 

To define optimal intrathecal agents for use with effective chemotherapy with minimal increase in toxicity nad/or burden of therapy for children with HR-ALL. Patient will be randomized to post-induction therapy with a modified BFM backbone that includes a single Interim Maintenance (IM) phase with high dose methotrexate and a single Delayed Intensification (DI) phase with either intrathecal methotrexate only.

Study Number: 

NCG 206911

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01406756

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.